Oxford Immunotec Global (OXFD) Stock Rating Upgraded by BidaskClub

Share on StockTwits

Oxford Immunotec Global (NASDAQ:OXFD) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Thursday.

OXFD has been the topic of a number of other reports. ValuEngine downgraded shares of Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 1st. Piper Jaffray Companies restated an “overweight” rating on shares of Oxford Immunotec Global in a research report on Sunday, November 11th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $16.67.

Oxford Immunotec Global stock traded up $0.02 during trading hours on Thursday, reaching $14.90. 106,517 shares of the company’s stock traded hands, compared to its average volume of 104,300. Oxford Immunotec Global has a fifty-two week low of $10.00 and a fifty-two week high of $19.19. The company has a market cap of $387.25 million, a PE ratio of -10.96 and a beta of 0.11.

Oxford Immunotec Global (NASDAQ:OXFD) last released its earnings results on Friday, November 9th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.14). Oxford Immunotec Global had a negative net margin of 12.51% and a negative return on equity of 41.15%. The business had revenue of $16.10 million for the quarter, compared to analyst estimates of $33.60 million. During the same quarter in the previous year, the company posted ($0.70) earnings per share. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. On average, research analysts expect that Oxford Immunotec Global will post -1.09 earnings per share for the current fiscal year.

In other news, CEO Peter Wrighton-Smith sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 10th. The stock was sold at an average price of $14.91, for a total value of $149,100.00. Following the completion of the sale, the chief executive officer now directly owns 423,469 shares of the company’s stock, valued at approximately $6,313,922.79. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard A. Sandberg sold 3,000 shares of the company’s stock in a transaction dated Thursday, November 1st. The shares were sold at an average price of $15.50, for a total value of $46,500.00. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at $139,500. The disclosure for this sale can be found here. Corporate insiders own 6.61% of the company’s stock.

Several hedge funds have recently made changes to their positions in the company. Rhumbline Advisers increased its stake in Oxford Immunotec Global by 45.8% during the 2nd quarter. Rhumbline Advisers now owns 32,861 shares of the company’s stock worth $424,000 after purchasing an additional 10,320 shares in the last quarter. Russell Investments Group Ltd. increased its stake in Oxford Immunotec Global by 19.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 97,445 shares of the company’s stock worth $1,257,000 after purchasing an additional 16,070 shares in the last quarter. BlackRock Inc. increased its stake in Oxford Immunotec Global by 10.0% during the 2nd quarter. BlackRock Inc. now owns 1,279,324 shares of the company’s stock worth $16,490,000 after purchasing an additional 116,814 shares in the last quarter. Citadel Advisors LLC bought a new stake in Oxford Immunotec Global during the 2nd quarter worth approximately $1,029,000. Finally, Renaissance Technologies LLC increased its stake in Oxford Immunotec Global by 84.7% during the 2nd quarter. Renaissance Technologies LLC now owns 21,058 shares of the company’s stock worth $271,000 after purchasing an additional 9,658 shares in the last quarter. 90.94% of the stock is owned by institutional investors.

About Oxford Immunotec Global

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Read More: Institutional Investors

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

IslaCoin Price Hits $0.17 on Exchanges
IslaCoin Price Hits $0.17 on Exchanges
WP Carey Inc  Given Average Recommendation of “Hold” by Brokerages
WP Carey Inc Given Average Recommendation of “Hold” by Brokerages
Medtronic PLC  Given Consensus Recommendation of “Buy” by Analysts
Medtronic PLC Given Consensus Recommendation of “Buy” by Analysts
Zen Protocol Reaches 24 Hour Trading Volume of $240,660.00
Zen Protocol Reaches 24 Hour Trading Volume of $240,660.00
Zynerba Pharmaceuticals  Upgraded by Zacks Investment Research to Buy
Zynerba Pharmaceuticals Upgraded by Zacks Investment Research to Buy
Po.et Price Up 5.6% Over Last 7 Days
Po.et Price Up 5.6% Over Last 7 Days


Leave a Reply

© 2006-2019 Ticker Report